Brief: Daré Bioscience Announces Subject Screening For Mid-stage Respond Study Of Sildenafil Cream

Dare Bioscience

01/11/2022 12:09

Nov 1 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES SUBJECT SCREENING FOR PHASE 2B
RESPOND
STUDY OF SILDENAFIL CREAM, 3.6% IN WOMEN WITH FEMALE SEXUAL
AROUSAL DISORDER COMPLETE
    * DARE BIOSCIENCE INC - TOPLINE DATA OF PHASE 2B RESPOND
STUDY
TARGETED FOR 2Q-2023
    * DARE BIOSCIENCE INC - IF CLINICAL DEVELOPMENT IS
SUCCESSFUL,
SILDENAFIL CREAM, 3.6% HAS POTENTIAL TO BE FIRST FDA-APPROVED
FSAD TREATMENT OPTION
    * DARE BIOSCIENCE INC - APPROXIMATELY 160 TO 170 SUBJECTS IN
TOTAL
ARE EXPECTED TO COMPLETE CLINICAL STUDY
    * DARE BIOSCIENCE INC - APPROXIMATELY 100 SUBJECTS HAVE
COMPLETED
ALL STUDY ASSESSMENTS TO DATE

Source text for Eikon:  ID:nGNX1K7Gtp 
Further company coverage:  DARE.O 
 ((Reuters.Briefs@thomsonreuters.com;))